RGNX

Morgan Stanley analyst Vikram Purohit maintained a Buy rating on RegenXBio (RGNX - Research Report) today and set a price target of $50.00. The company's shares opened today at $21.71.Purohit covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Ascendis Pharma, and RegenXBio. According to TipRanks, Purohit has an average return of -24.4% and a 18.75% success rate on recommended stocks. RegenXBio has an analyst consensus of Moderate Buy, with a price target consensus of $40.29, an 85.58% upside from current levels. In a report released on November 18, Berenberg Bank also initiated coverage with a Buy rating on the stock with a $61.00 price target.
https://www.tipranks.com/news/blurbs/morgan-stanley-remains-a-buy-on-regenxbio-rgnx-2?utm_source=advfn.com&utm_medium=referral